These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 34175693

  • 1. Systemic bevacizumab as adjuvant therapy for recurrent respiratory papillomatosis in children: A series of three pediatric cases and literature review.
    Enrique OH, Eloy SH, Adrian TP, Perla V.
    Am J Otolaryngol; 2021; 42(5):103126. PubMed ID: 34175693
    [Abstract] [Full Text] [Related]

  • 2. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Institution's Experience.
    So RJ, Rayle C, Joo HH, Huang EY, Seiwert TY, Raabe EH, Best SR.
    Laryngoscope; 2024 Jul; 134(7):3253-3259. PubMed ID: 38525973
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant Intralesional Bevacizumab in Pediatric and Adult Populations With Recurrent Respiratory Papillomatosis: A Systematic Review.
    Gately UE, Zhang N, Karle WE, Lott DG.
    Ann Otol Rhinol Laryngol; 2024 Oct; 133(10):841-847. PubMed ID: 39044374
    [Abstract] [Full Text] [Related]

  • 4. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases.
    Bedoya A, Glisinski K, Clarke J, Lind RN, Buckley CE, Shofer S.
    Am J Case Rep; 2017 Jul 31; 18():842-846. PubMed ID: 28757601
    [Abstract] [Full Text] [Related]

  • 5. Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.
    Collette F, Lawson G, Hassid S, Delahaut G, Bachy V, Van Der Vorst S, Faugeras L, Gilliaux Q, D'Hondt L.
    Head Neck; 2023 May 31; 45(5):1071-1079. PubMed ID: 36840929
    [Abstract] [Full Text] [Related]

  • 6. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey.
    Best SR, Mohr M, Zur KB.
    Laryngoscope; 2017 Oct 31; 127(10):2225-2229. PubMed ID: 28657692
    [Abstract] [Full Text] [Related]

  • 7. Recurrent laryngeal papillomatosis: multimodal therapeutic strategies. Literature review and multicentre retrospective study.
    Bertino G, Pedretti F, Mauramati S, Filauro M, Vallin A, Mora F, Crosetti E, Succo G, Peretti G, Benazzo M.
    Acta Otorhinolaryngol Ital; 2023 Apr 31; 43(Suppl. 1):S111-S122. PubMed ID: 37698108
    [Abstract] [Full Text] [Related]

  • 8. Use of 532-nm pulsed potassium titanyl phosphate laser and adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children: initial experience.
    Maturo S, Hartnick CJ.
    Arch Otolaryngol Head Neck Surg; 2010 Jun 31; 136(6):561-5. PubMed ID: 20566906
    [Abstract] [Full Text] [Related]

  • 9. Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosis.
    Allen CT, Lee S, Norberg SM, Kovalovsky D, Ye H, Clavijo PE, Hu-Lieskovan S, Schlegel R, Schlom J, Strauss J, Gulley JL, Trepel J, Hinrichs CS.
    J Immunother Cancer; 2019 May 03; 7(1):119. PubMed ID: 31053174
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Systemic bevacizumab for recurrent respiratory papillomatosis.
    Baday YI, Ongkasuwan J, Venkatramani R.
    Int J Pediatr Otorhinolaryngol; 2020 Nov 03; 138():110352. PubMed ID: 32906078
    [Abstract] [Full Text] [Related]

  • 12. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management.
    Stamataki S, Nikolopoulos TP, Korres S, Felekis D, Tzangaroulakis A, Ferekidis E.
    Head Neck; 2007 Feb 03; 29(2):155-62. PubMed ID: 17022088
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children.
    Rogers DJ, Ojha S, Maurer R, Hartnick CJ.
    JAMA Otolaryngol Head Neck Surg; 2013 May 03; 139(5):496-501. PubMed ID: 23681032
    [Abstract] [Full Text] [Related]

  • 15. Outcomes of bevacizumab and cidofovir treatment in HPV-associated recurrent respiratory papillomatosis - review of the literature.
    Jackowska J, Piersiala K, Klimza H, Wierzbicka M.
    Otolaryngol Pol; 2018 Jun 12; 72(4):1-8. PubMed ID: 30190442
    [Abstract] [Full Text] [Related]

  • 16. Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine.
    Mészner Z, Jankovics I, Nagy A, Gerlinger I, Katona G.
    Int J Pediatr Otorhinolaryngol; 2015 Feb 12; 79(2):262-6. PubMed ID: 25496821
    [Abstract] [Full Text] [Related]

  • 17. Recurrent respiratory papillomatosis.
    Kashima HK, Mounts P, Shah K.
    Obstet Gynecol Clin North Am; 1996 Sep 12; 23(3):699-706. PubMed ID: 8869953
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Tracheobronchial and pulmonary papillomatosis without involvement of the larynx treated with intravenous Bevacizumab in a child].
    Cuestas G, Rodríguez V, Doormann F, Bellia Munzón P, Bellia Munzón G.
    Arch Argent Pediatr; 2019 Feb 01; 117(1):e72-e76. PubMed ID: 30652461
    [Abstract] [Full Text] [Related]

  • 20. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis.
    Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A.
    Ann Otol Rhinol Laryngol; 2014 Mar 01; 123(3):214-21. PubMed ID: 24633948
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.